Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced or Unresectable Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT03975647
What this trial is testing

Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 466
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Not applicableWithdrawnNCT02616224
What this trial is testing

Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche
Large-scale testing (Phase 3)Study completedNCT00006459
What this trial is testing

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Study completedNCT04603183
What this trial is testing

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Who this might be right for
Breast Cancer Metastatic
MedSIR 162
Testing effectiveness (Phase 2)UnknownNCT04129996
What this trial is testing

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT05852691
What this trial is testing

Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 83
Testing effectiveness (Phase 2)Ended earlyNCT03149549
What this trial is testing

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Who this might be right for
Solid Tumor, AdultBreast CancerNon Small Cell Lung Cancer+2 more
CytomX Therapeutics 99
Large-scale testing (Phase 3)Active Not RecruitingNCT06343948
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Who this might be right for
HR+HER2- Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 383
Not applicableStudy completedNCT03025711
What this trial is testing

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine

Who this might be right for
Breast Neoplasms
BELEN RUIZ-ANTORAN 220
Large-scale testing (Phase 3)Not Yet RecruitingNCT07393321
What this trial is testing

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical 210
Not applicableStudy completedNCT02913456
What this trial is testing

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 629
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Large-scale testing (Phase 3)Looking for participantsNCT07413939
What this trial is testing

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Who this might be right for
HER2-positive Breast Cancer
Hoffmann-La Roche 650
Large-scale testing (Phase 3)Active Not RecruitingNCT06316531
What this trial is testing

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 274
Testing effectiveness (Phase 2)Active Not RecruitingNCT06445400
What this trial is testing

BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 83
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Not applicableLooking for participantsNCT06993506
What this trial is testing

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
HER2-negative Breast CancerRecurrenceMetastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07623642
What this trial is testing

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Who this might be right for
Uterine Cervical NeoplasmsTriple Negative Breast NeoplasmsProstatic Neoplasms+8 more
GV20 Therapeutics 227
Next Page